LNP based Base Editing Platform for Precision CAR-T

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Although CAR-T therapy holds remarkable promise, its clinical translation is often hampered by production bottlenecks, risks of on-target/off-tumor toxicity, and the genome-integrating nature of viral delivery systems. Our LNP-based base-editing platform overcomes these obstacles through a non-integrating, transient approach that introduces precise point mutations in primary T cells while avoiding DNA double-strand cleavage. We provide an end-to-end customizable service, from tailored sgRNA selection and lipid nanoparticle assembly to optimized T-cell engineering protocols. With high on-target accuracy, low indel formation, and preserved cellular function, our system offers you a robust, versatile toolkit for accelerated development of safer, more effective CAR-T products.

Introduction

Base editing is a next-generation CRISPR-derived technology that enables precise single-nucleotide conversions without inducing double-strand breaks, thereby minimizing genotoxicity risks such as chromosomal translocations. Lipid nanoparticles (LNPs) provide a non-viral, transient delivery platform for base-editing components, overcoming the limitations of viral vectors and enabling efficient, scalable ex vivo or in vivo T cell engineering. In CAR-T therapy, this LNP-based base-editing platform facilitates multiplexed gene knockouts and site-specific CAR knock-in within a single intervention, enhancing safety, preserving T cell fitness, and accelerating the development of off-the-shelf allogeneic cell products.

Fig.1 Therapeutic genome editing via base editors is performed in hematopoietic stem cells. (OA Literature) Fig.1 Base editor-mediated approaches enable gene therapy within hematopoietic stem cell populations.¹

Our Service

Our next-generation, non-viral platform seamlessly integrates advanced lipid nanoparticles (LNPs) with high-fidelity base editors to enable precise, multiplexed genome engineering in T cells. By eliminating viral vector constraints and minimizing double-strand breaks, we deliver highly efficient, off-the-shelf CAR-T manufacturing with unmatched safety.

What We Can Offer

We offer a comprehensive, end-to-end evaluation platform for precision CAR-T development, seamlessly integrating rigorous LNP characterization, deep-coverage base editing efficiency and safety profiling, and robust in vitro functional assays to ensure maximum therapeutic potency and safety.

Featured services of LNP-based base editing platform for precision CAR-T at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Base Editor mRNA.
CAR Cargo.
PBMC or Purified T Cells.

Key Steps:

Workflow of LNP-based base editing platform for precision CAR-T at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Base Editing Efficiency Assessment Data.
CAR Cell Products.

Key Advantages

Superior Genomic Safety: By catalyzing single-nucleotide transitions without creating double-strand breaks (DSBs), our platform maintains high genomic integrity and mitigates chromosomal translocation risks below detection limits during multiplex editing.
Enhanced Cell Viability and Stemness: Leveraging gentle, endogenous endocytosis instead of harsh electroporation avoids physical membrane damage, preserving over 90% cell viability alongside crucial early-memory TSCM and TCM phenotypes for prolonged in vivo persistence.
Transient Expression with Minimal Off-Target Risks: The rapid kinetics of LNP-delivered mRNA ensure a narrow therapeutic window where the base editor is swiftly degraded post-editing, significantly minimizing off-target activity compared to long-term viral integration.
Streamlined Multiplex Editing Efficiency: The platform enables highly efficient, one-step simultaneous knockouts of multiple loci via the co-encapsulation of base editor mRNA and diverse sgRNAs, yielding knockout rates exceeding 90%.

FAQ

Q1: What distinct advantages does LNP-mediated base editor delivery offer over conventional electroporation or viral vectors?

A1: LNP delivery provides a safer, highly scalable alternative for T-cell engineering. Utilizing natural endocytosis preserves cell viability and expansion potential, avoiding the mechanical damage of electroporation. Furthermore, LNPs deliver transient mRNA that degrades rapidly without genomic integration, eliminating insertional oncogenesis risks and minimizing off-target events.

Q2: Why is base editing preferred over standard CRISPR-Cas9 cleavage for precision CAR-T engineering?

A2: Base editing is preferred over CRISPR-Cas9 because it enables precise single-nucleotide transitions without inducing DSBs. While DSBs often trigger catastrophic chromosomal translocations and apoptosis during multi-locus multiplexing, base editing avoids these disruptions entirely, securing the genomic integrity required for safe, sophisticated universal CAR-T therapies.

Why Choose Us?

Leveraging synergistic expertise in ionizable lipid design and high-fidelity base editors, our platform delivers multiplexed, off-the-shelf gene editing with unparalleled precision and minimal off-target risks. We empower your CAR-T therapeutics with superior efficacy, streamlined manufacturing, and highly scalable, non-viral delivery solutions.

Customer Reviews

"Transitioning to this LNP-based base editing platform has completely transformed our allogeneic CAR-T pipeline. Unlike traditional electroporation, which severely compromises cell viability, this platform achieves over 90% T cell survival. It allowed us to precisely knock out multiple checkpoint genes simultaneously without inducing double-strand breaks, drastically reducing the risk of chromosomal translocations and ensuring an incredibly safe, potent cell product. Our team has utilized this CRISPR-Enabled UCAR-T platform for over eighteen months to generate allogeneic candidates. " Dr. A* V*.

"The absolute precision of this base editing platform is unmatched. By utilizing LNP-mediated transient mRNA delivery, we achieved highly efficient single-nucleotide modifications while completely avoiding long-term off-target risks. The edited CAR-T cells demonstrated robust tumor clearance in our preclinical models." S* J*, PhD

How to contact us?

Ready to revolutionize your cell therapy pipeline? Partner with us to leverage our cutting-edge LNP-based base editing platform and accelerate your precision CAR-T breakthroughs. Reach out today to discuss your project specifications and receive a tailored quote from our expert team. Let's transform the future of immunotherapy together.

Reference

Zhang, Chengpeng et al. "Base Editors-Mediated Gene Therapy in Hematopoietic Stem Cells for Hematologic Diseases." Stem cell reviews and reports vol. 20,6 (2024): 1387-1405. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1007/s12015-024-10715-5.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.